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Myocardial infarction (MI) (i.e. heart attack) is the permanent death (necrosis) of heart muscle 
resulting from prolonged lack of oxygen supply (ischemia) (NHLBI, 2015). Without immediate 
restoration of blood flow, death of heart muscle will ensue (NHLBI, 2015). Every year, more 
than one million Americans experience MI, and approximately half of them die (Medline Plus, 
2015). Though successful return to normal activities post-infarction is highly possible, 
individuals are nevertheless at risk for complications due to ischemic cardiac tissue (Brown, 
2015). The mammalian heart has poor regenerative capabilities – cardiomyocytes cannot 
proliferate; therefore, cardiac muscle does not repair itself. Recently, the notion that adult 
cardiomyocytes are unable to proliferate has been challenged (Bergmann, 2009). However, 
despite intensive research efforts, the mechanisms governing cardiomyocyte cell cycle reentry 
and proliferation remain unknown. The Dzau lab has recently identified a novel paracrine protein 
synthesized by mesenchymal stem cells, C3orf58, which they have termed hypoxia and Akt 
induced stem cell factor (HASF) (Beigi, 2013). Preliminary data has indicated that it harbors the 
capacity to promote neonatal and adult cardiomyocyte proliferation, and thereby, cardiac 
regeneration (Beigi, 2013). Previously, I hypothesized that HASF promoted cardiomyocyte 
proliferation via the CAK complex/ERK signaling pathway (Baksh, 2016). However, I observed 
that it was IGF-1, not HASF, that promoted cardiomyocyte proliferation via the CAK 
complex/AKT signaling pathway (Baksh, 2016). Therefore, the goal of this study was to 
delineate the molecular pathway by which IGF1-AKT-activated CAK complex promotes 
cardiomyocyte proliferation. IGF1-activated CDKs and cyclins were identified by incubating 
cells with IGF-1 for 12hr and performing Western blot analysis, probing with cyclin E1 and 
pCDK2 antibodies. Additionally, the AKT signaling pathway was inhibited by triciribine to 
 iii 
assess to effect of AKT inhibition on CDK2 phosphorylation and cyclin E1 expression. IGF-1 
was observed to enhance CDK2 phosphorylation via AKT stimulation and CAK activation. This 
finding will serve to enhance our understanding of the mechanisms underlying cardiomyocyte 
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Myocardial infarction (MI) is the permanent death of heart muscle resulting from 
prolonged lack of oxygen supply (NHLBI, 2015). The blockage is a result of plaque 
rupture and subsequent blood clot formation – a coronary artery may become completely 
blocked if the blood clot grows large enough (NHLBI, 2015). If blood flow is not 
immediately restored the result is death of heart muscle (NHLBI, 2015). Every year, 
more than one million Americans experience MI, and approximately half of them die 
(Medline Plus, 2015). Though countless individuals successfully return to normal 
activities post-infarction, they are nevertheless at risk for complications due to ischemic 
cardiac tissue (CDC, 2015). These complications include arrhythmias and heart block, 
hypotension and congestive heart failure (due to ischemic tissue causing abnormal filling 
[“diastolic dysfunction”] or abnormal emptying [“systolic dysfunction”]) (Brown, 2015). 
Several days post-infarction, mechanical complications may arise as a result of “yellow 
softening” of the myocardial tissue, and pericarditis may ensue as well (Brown, 2015). 
The mammalian heart has poor regenerative capabilities – unlike other cells, 
cardiomyocytes are terminally differentiated and possess limited capabilities for cell 
cycle reentry, and thus, do not undergo division (Kikuchi, 2012). Therefore, cardiac 
muscle does not have the ability to repair itself, and any damage it sustains is irreversible. 
 
In recent years, the concept of adult cardiomyocytes lacking proliferative abilities has 
been challenged (Bergmann, 2009), and scientists have been avidly investigating ways to 
reestablish mitotic activity in cardiomyocytes for myocardial repair and restoration of 
normal cardiac function post-infarction. Though cardiomyocyte proliferation has been 
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observed, it is not sufficient for complete myocardial regeneration (Kishore, 2000). 
Despite the intensive research efforts, the mechanisms underlying cardiomyocyte cell 
cycle reentry and proliferation remain unclear. However, the Dzau lab has recently 
identified a novel paracrine protein synthesized by mesenchymal stem cells, C3orf58, and 
has termed it hypoxia and Akt induced stem cell factor (HASF). They have demonstrated 
its capacity to promote neonatal and adult cardiomyocyte proliferation, and thereby, 
cardiac regeneration (Beigi, 2013). Via in vitro studies, Beigi et al. observed that HASF-
mediated cardiomyocyte proliferation was dependent upon the stimulation of cyclin-
dependent kinase 7 (CDK7).  
 
Among the countless proteins essential to cell cycle control, cyclin-dependent kinases 
(CDKs) are the most significant. CDKs are small (30 – 40 kD) serine/threonine kinases; 
they are inactive in the monomeric form, requiring an activating subunit to exert their 
protein kinase effects (Lodish, 2013; p.884). Though mammalian cells harbor as many as 
nine CDKs, CDK1, CDK2, CDK4, and CDK6 have been shown to mediate progression 
of the cell cycle (Lodish, 2013; p.884). By associating with various cyclins, these CDKs 
regulate the transition of different stages of the cell cycle. CDKs catalyze the 
phosphorylation of proteins critical to cell cycle progression solely in the presence of 
cyclins (as indicated by their names) (Nature, 2014). Cyclins themselves harbor no 
enzymatic activity (Nature, 2014) and have been characterized by three primary features: 
1) they associate with and activate CDKs ; 2) they are solely present during the stage of 
the cell cycle they activate and are absent during the others, and 3) they trigger a series of 
events to prepare for the approaching cell cycle stage, in addition to regulating their 
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designated cell cycle stage (Lodish, 2013; p.885). CDK4 and CDK6 are G1 CDKs and 
bind cyclin D2, promoting entry into the cell cycle; CDK2 is a G1/S phase and S phase 
CDK and binds cyclins A2 and E1, preparing cells for the S phase; CDK1 is a mitotic 
CDK and binds cyclins A2 and B1, initiating mitosis (Lodish, 2013; p. 884).              
  
Image: Suryadinata, 2010. 
 
CDK7 binds cyclin-H, and additionally, MAT1 (ménage-à-trois 1), a protein that alters 
the complex’s substrate specificity (Patel, 2010) – together, these proteins form the CDK-
activating kinase (CAK). CAK is responsible for phosphorylating various CDKs, 
including CDK1, CDK2, and CDK6 (Lolli, 2005), proteins critical in cell cycle 
progression, and thereby, cellular proliferation.  
 
HASF activates the Ras–Raf–MEK–ERK (also referred to as MAPK/ERK) signaling 
pathway (Hodgkinson, C., personal communication, Oct 2015), which regulates diverse 
biological processes, including cellular proliferation (Liao, 2013). Upon exogenous 
stimulation, the GTPase Ras is activated (Lodish, 2013; p.739). The protein kinase Raf 
exists in an inactive state in the unstimulated cell – Ras activation activates Raf kinase 
activity, and Raf phosphorylates MEK (Lodish, 2013; p.738). MEK subsequently 
 4 
phosphorylates MAPK/ERK, which translocates to the nucleus and stimulates numerous 
transcription factors (Lodish, 2013; p.738). These transcription factors promote 
expression of genes significant to cellular proliferation, including CDKs and cyclins 
(Chang, 2003).  
 
Insulin-like growth factor 1 (IGF-1) is a hormone found in the blood that mediates the 
effects of growth hormone (GH) and is essential in early childhood tissue and bone 
growth (Snyder and Taylor). IGF-1, when bound to its receptor IGF1R, activates the 
Ras–Raf–MEK–ERK pathway and the PI3K/AKT signaling pathway. The PI3K/AKT 
pathway, similar to ERK pathway, mediates an array of biological processes, including 
cellular proliferation (Schiaffino, 2011). Receptor binding results in autophosphorylation 
of its intrinsic tyrosine kinase, producing docking sites for insulin receptor substrate 
(IRS), which is subsequently phosphorylated by IGF1R (Schiaffino, 2011). pIRS serves 
as a docking site for phosphatidylinositol-3-kinase (PI3K); PI3K subsequently 
phosphorylates membrane phospholipids, producing phosphoinositide-3,4,5-triphosphate 
(PIP3) from phosphoinositide-4,5-biphosphate (PIP2) (Schiaffino, 2011). PIP3 acts as yet 
another docking site for phosphoinositide-dependent kinase 1 (PDK1) and Akt 
(Schiaffino, 2011). PDK1 subsequently phosphorylates Akt at serine 308, resulting in Akt 
activation (Schiaffino, 2011).  
 
Recently, the Dzau lab has identified a receptor for HASF – IGF1R. Using a yeast two-
hybrid screen and co-immunoprecipitation, it was demonstrated that HASF binds IGF1R 
(Hodgkinson, C., personal communication, Oct 2015). Additionally, the potential of 
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HASF to stimulate IGF1R and IGF1R-mediated signaling pathways was examined – both 
HASF and the control, IGF-1, exhibited autophosphorylation of tyrosine-1149 (signifying 
receptor activation) and promoted ERK phosphorylation (Hodgkinson, C., personal 
communication, Oct 2015) via the Ras-Raf signaling pathway (Troncoso, 2014). 
Therefore, it was concluded that HASF activates the Ras-Raf-MEK-ERK pathway.  
 
LL-37 is the cleaved, mature C-terminal peptide of human cathelicidin antimicrobial 
protein-18 (hCAP-18) and contributes to an array of biological processes such as 
apoptosis, angiogenesis, and would healing (Girnita, 2012). Like HASF and IGF-1, LL-
37 binds to IGF1R; however, it activates only the ERK signaling pathway, not the 
PI3K/AKT signaling pathway (Girnita, 2012).   
 
The goal of this study is to characterize the molecular mechanisms by which IGF1-AKT-
activated CAK complex promotes cardiomyocyte proliferation. Previously, I 
hypothesized that cardiomyocyte proliferation was mediated by HASF-ERK-CAK. 
However, I observed that it was IGF1-AKT-CAK that mediates cardiomyocyte 
proliferation (Baksh, 2016). Therefore, my aim this semester is to further delineate the 
mechanisms by which IGF1-mediated cardiomyocyte proliferation occurs. To achieve 
this, the CDKs and cyclins activated by IGF-1 will be identified. Additionally, the effect 
of CAK knockdown and AKT inhibition on CDK phosphorylation and cyclin expression 
will be assessed. The results this study will aid in our understanding of the mechanisms 
governing cardiomyocyte cell cycle reentry and will thus make IGF-1 a potential 
therapeutic candidate for myocardial repair post-infarction.  
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Methods and Materials  
siRNA mediated knockdown of the CAK complex 
I began with knockdown of CDK7and CCNH. A day prior to infection, 130,000 H9C2 
cells/well were seeded onto T25 flasks. The day the transfection was performed, 10 uM 
siRNA (6.57 uL) was diluted in optimem-serum-free media (328.75 uL, Optimem-SF, 
Invitrogen). In a different tube, lipofectamine 2000 (19.72 uL) was added to Optimem-SF 
(328.75 uL). Solutions were subsequently combined and incubated for 5min at room 
temperature. 328.75 uL of the transfection complex was added to each flask. Transfection 
complexes were replaced the next day with fresh growth media (1X DMEM, 10% FBS, 
1% Pen/Strep). 
 
Immunoblotting to confirm knockdown of the CAK complex 
Three days post-transfection, protein was extracted using 350 ul lysis buffer (1 ml of lysis 
buffer – 62.5 ul Trizma HCl buffer [1M; pH 7.4], 100 ul 10% SDS, 10 ul protease 
inhibitors (Roche), 100 ul phosphatase inhibitors (Sigma Aldrich), and 727.5 ul H2O) per 
well. Protein (20 ug) was denatured by boiling for five minutes and then loaded into wells 
of a 10-well gel and run for 2h at 120V. Membranes were blocked for one hour in 5% 
milk (nonfat dry milk [Bio-Rad] in TBST [2.4g Tris, 8g NaCl, 1 ml Tween 20 in 1L 
water]; pH 7.4 – 7.5) and subsequently probed with B-tubulin (#2146, Cell Signaling 
Technologies), CDK7 (#2090, Cell Signaling Technologies), or cyclin H (#2927, Cell 
Signaling Technologies) antibodies at a 1:1000 concentration in 5% milk overnight at 
4°C. The following day, membranes were washed 3 times for 5min each in TBST and 
probed with anti-rabbit secondary antibody (#7074, Cell Signaling Technologies) at a 
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1:1000 concentration in 5% milk for 75 minutes at room temperature. Membranes were 
subsequently washed in TBST, placed in ECL for 2min (Amersham ECL Plus™, GE 
Healthcare; 1:1 ratio of solutions A and B), and visualized via G:BOX Chemi XX6 
(Syngene).  
 
To assess proliferation of H9C2s with knockdown of CAK  
A day prior to transfection, H9C2s were seeded onto 12-well plates at 20,000 cells/well. 
The following day, cells underwent CDK7 and CCNH knockdown as described above. 
Three days post-transfection, cells were serum starved in serum-free media for 6hr and 
were treated with the following conditions: 1) no treatment; 2) Lipofectamine; 3) siNeg 
#1; 4) siNeg #2; 5) HASF+CAK knockdown; 6) HASF+siNeg+Lipofectamine 7) IGF-
1+CAK knockdown; 8) IGF-1+siNeg+Lipofectamine 9) LL-37+CAK knockdown; and 
10) LL-37+siNeg+Lipofectamine. One day post-treatment, proliferation was assessed via 
BrdU staining – BrdU (0.03 mg/mL) was added to each well and incubated at 37°C for 
24h. Following 24h, media was aspirated and cells were fixed in 70% ice-cold ethanol for 
5min and subsequently washed in PBS 3 times for 5min each. 1.5 M HCl was then added 
to the cells for 30m, followed by 2 washes in PBS for 5m each. The cells were 
subsequently incubated in blocking buffer (0.3% Triton, 5% normal goat serum in PBS) 
for 1h. Afterwards, anti-BrdU antibody (#5292, Cell Signaling Technologies) was added 
to the cells at a concentration of 1:500 in antibody dilution buffer (1% BSA in PBS) 
overnight at 4°C with constant agitation. The next day, cells underwent PBS washes, 3 
times for 5min each, and were probed with goat anti-mouse secondary antibody (Alexa 
Fluor 488 A-11001, ThermoFisher) at a concentration of 1:500 in antibody dilution 
 8 
buffer for 1hr. During the last PBS wash following secondary incubation, DAPI (1mg/ml) 
was added to each well. Cells were visualized and were counted with ImageJ.      
 
To assess proliferation of H9C2s with inhibition of the ERK and PI3K/AKT pathways 
Cells were trypsinized (0.05% trypsin/EDTA) and seeded onto 12-well plates at 20,000 
cells/well. One day post-seeding, cells were serum starved for 6hr and pre-treated with a 
MEK inhibitor, U0126 (10 uM, Cell Signaling Technologies), and an AKT inhibitor, 
Triciribine (10 uM, Selleckchem), or vehicle for 2hr prior to the end of serum starvation. 
Following serum starvation, cells were treated with ligands and their vehicle, 
sterile/endotoxin-free water (5 ul/ml) or DMSO (1ul/ml), yielding the following 
conditions: 1) H2O/no treatment; 2) H2O+DMSO; 3) H2O+U0126; 4) H2O+triciribine; 
5) HASF; 6) HASF+DMSO; 7) HASF+U0126; 8) HASF+triciribine; 9) IGF-1; 10) IGF-
1+DMSO; 11) IGF-1+U0126; 12) IGF-1+triciribine; 13) LL-37; 14) LL-37+DMSO; 15) 
LL-37+U0126; 16) LL-37+triciribine. Upon 12hr of treatment, cells were stained with 
BrdU for 24h and assessed for proliferation as described above. Cells were visualized and 
were counted with ImageJ. 
 
To identify the CDKs and cyclins activated by IGF-1 in cardiomyocytes 
Approximately 780,000 H9C2 cells were seeded into T150 flasks; upon 50 – 70% 
confluence, cells were serum starved in serum-free media (1X DMEM, 1% Pen/Strep) for 
6hr and treated with IGF-1 (1 uL/mL) for 12h. Upon ~80% confluency, at which point 
the cells were in a linear growth phase, protein was extracted using 500 uL lysis buffer. 
Following boiling for five minutes, 40 ug of protein was loaded into wells of a 10-well 
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gel and run for 2hr at 120V. Membranes were blocked for one hour in 5% milk (nonfat 
dry milk [Bio-Rad] in TBST [2.4g Tris, 8g NaCl, 1 ml Tween 20 in 1L water]; pH 7.4 – 
7.5) and subsequently probed with pCDK2 (#2561, Cell Signaling Technologies), cyclin 
A2 (#4656, Cell Signaling Technologies), cyclin B1 (#4138, Cell Signaling 
Technologies), cyclin E1 (#4129, Cell Signaling Technologies), and B-tubulin (#2146, 
Cell Signaling Technologies), at a 1:1000 concentration in 5% BSA overnight at 4°C 
with constant agitation. The following day, membranes were washed 3 times with TBST 
for 5min each and probed with anti-rabbit secondary antibody (#7074, Cell Signaling 
Technologies) at a 1:1000 concentration in 5% BSA for 75m at room temperature. 
Membranes were subsequently washed in TBST, placed in ECL for 2min (Amersham 
ECL Plus™, GE Healthcare; 1:1 ratio of solutions A and B), and visualized via G:BOX 
Chemi XX6 (Syngene). 
To determine the effect of CAK knockdown on IGF1-mediated activation of CDKs and 
cyclins. 
A day prior to infection, 780,000 H9C2 cells were seeded into T150 flasks. The day the 
transfection was performed, 10 uM siRNA (39.48 uL) was diluted in optimem-serum-free 
media (1,972.5 uL, Optimem-SF, Invitrogen). In a different tube, lipofectamine 2000 
(118.38 uL) was added to Optimem-SF (1,972.5 uL). Solutions were subsequently 
combined and incubated for 5m at room temperature. 1,972.5 uL of the transfection 
complex was added to each flask. Media was changed the following day to standard 
growth media (1X DMEM, 10% FBS, 1% Pen/Strep). Three days post-transfection, cells 
were serum starved and treated with IGF-1 as described above. Western blot was used to 
evaluate protein expression as described above.  
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To determine the effect of AKT inhibition on IGF1-mediated activation of CDKs and 
cyclins. 
Cells were seeded and serum starved as described above and pre-treated with the AKT 
inhibitor triciribine (10 uM, Selleckchem) 2h prior to the end of serum starvation. 
Following serum starvation, cells were treated with ligands as described above. 
Afterwards, protein was extracted and Western blot analysis was performed. 
 
To validate CAK-mediated phosphorylation of CDKs and activation of cyclins.   
DpnI Cloning 
Initially, a CDK7 plasmid was purchased (#MR205228, Origene), and mutant primers 
were designed complementary to the CDK7 binding site (position 41; a lysine was 
converted to an alanine to induce a dominant negative mutation) and active site (position 
137; an alanine was converted to an aspartate to induce a constitutively active mutation) 
(Eurofins).  
Primer Sequence  
Mutant Primer 41F CGTCGCTATTCGCAAAATCAA 
Mutant Primer 41R TTGATTTTCGCAATAGCGACG 
Mutant Primer 137F CACAGGGCTCTGAAACCAA 
Mutant Primer 137R TTGGTTTCAGAGCCCTGTG 
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Afterwards, site-directed mutagenesis was performed via PCR (5331 Mastercycler 
Gradient, Eppendorf) using Phusion® High-Fidelity DNA Polymerase (#M0530, New 
England Biolabs). Three reactions were run –  
• one containing muPrimer-41: 41F + 41R 
• one containing muPrimer-137: 137F + 137R 
• one a control, containing muPrimer-41: 41F + 41R with no enzyme.  
One 50 uL reaction contained the following reagents:  
Reagent  50 µl Reaction Final Concentration 
5X Phusion HF Buffer 10 µl 1X 
10 mM dNTPs 1 µl 200 µM 
10 µM Forward Primer 2.5 µl 0.5 µM 
10 µM Reverse Primer 2.5 µl 0.5 µM 
DMSO  1.5 µl 3% 
Phusion DNA Polymerase 0.5 µl 1.0 units/50 µl PCR 
Template DNA 1 µl 10 ng 
Nuclease-free water Up to 50 ul  
 
Thermocycling conditions for PCR were as follows:  
STEP  TEMP  TIME  
Initial Denaturation 98°C 30 seconds 





30 seconds  
Final Extension 72°C 10 minutes 
Hold 4°C  
 
Following PCR, the PCR product underwent purification using QIAquick PCR 
Purification Kit (#28106, Qiagen). Purification was performed as per manufacturer’s 
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protocol and DNA eluted into 50ul of buffer EB (10mM Tris pH7.5). Afterwards, 10 uL 
of purified DNA was mixed with 1.67 uL 5X Nucleic Acid Sample Loading Buffer 
(#1610767, Bio-Rad) and loaded into wells of a 0.8% agarose gel (100 mL 1X TAE 
buffer, 0.8 g agarose, and 10 uL Green Gene Safe DNA dye [#RE0500, Southern 
Biolabs]). The gel was run at 120 V for 90m and visualized under UV. The following day, 
the PCR product underwent DpnI digestion – 26 uL of PCR product was digested in 3 uL 
CutSmart® Buffer (#B7204S, New England Biosciences) and 1 uL DpnI (#R0176, New 
England Biosciences) for 150m in a 37°C water bath. Next, bacterial transformation was 
performed using MAX Efficiency® DH5α™ Competent Cells (#18258012, 
ThermoFisher) per manufacturer’s instructions. 100 uL of competent cells was plated 
onto LB agar plates, which contained Kanamycin (50 ug/mL final concentration). Plates 
were placed in a 37°C incubator over-night and checked for colonies the next day.  
 
To troubleshoot the PCR, three separate PCRs were run, each containing the three 
aforementioned reactions (control, 41, and 137), with three different thermocycling 
conditions. The first PCR was run with an annealing temperature of 61°C, the second 
PCR was run with a denaturation time of 30sec, and the third PCR was run with an 
extension time of 270sec. For all three PCRs, the cycle number was increased to 35. 
Subsequently, PCR products were run on agarose gels, purified, digested, transformed, 
and plated onto agar plates with the addition of kanamycin as described above. 
Additionally, parental plasmid DNA was diluted 1:100, transformed, and plated to serve 




Mutagenic PCR was performed in a two-step reaction. The first step was to carry out the 
following four reactions:  
41 F mutant primer + VP 1.5 (5’) sequencing primer 
41 R mutant primer + XL39 (3’) sequencing primer 
137 F mutant primer + VP 1.5 (5’) sequencing primer 
137 R mutant primer + XL39 (3’) sequencing primer 
 
Thermocycling conditions for PCR were as follows:  
STEP  TEMP  TIME  
Initial Denaturation 98°C 30 seconds 





5 minutes  
Final Extension 72°C 10 minutes 







Sequencing primers were added during the last minute of the third PCR cycle. PCR 
products were run on agarose gels and purified as described above.  
 
Afterwards, a second PCR was run containing three reactions –  41F3’ + 41R5’, 137F3’ + 
137R5’, and a control containing solely 41F3’. VP 1.5 and XL39 were added during the 
last minute of the third PCR cycle. Subsequently, PCR products were run on an agarose 
gel and visualized as described above.  
	 
To prevent parental plasmid contamination of PCR products, PCR was repeated as 
previously mentioned [(41 F mutant primer + VP 1.5 (5’) sequencing primer; 41 R 
mutant primer + XL39 (3’) sequencing primer; 137 F mutant primer + VP 1.5 (5’); 137 R 
mutant primer + XL39 (3’)], and bands were gel purified using the QIAquick® Gel 
Extraction Kit (#28704, Qiagen). Subsequently, the concentration of gel purified DNA 
was measured via NanoDrop™ 2000 –  
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Construct Concentration (ng/uL) 260/280 
41F3’ 26.3 1.93 
41R5’ 10  1.88 
137F3’ 37 1.90 
137R5’ 28.2 1.83 
A second PCR containing seven reactions was run – H2O control, 41F3’, 41R5’, 
41F3’+41R5’, 137F3’, 137R5’, and 137F3’+137R5’ – and cycle number was decreased 
to 25. PCR products were subsequently run on an agarose gel and visualized.   
 
To further optimize the PCR, gel purified DNA was run on an agarose gel at 
approximately equal molarities with double the concentration of Mg++ (from 1.5 mM to 
3 mM) and no more than 10 ng of DNA per well. The following are example 
calculations:  
Assuming 1 bp is 121 g/mol, 1.5 kb (size of construct) = 181,500 g/mol.  
41F3’ construct –  
26.3 ng/uL = 2.63 x 10-8 g/uL 
2.63 x 10-8 g / 1 x 10-6 L = 0.0263 g/L 
Molarity = 0.0263 g/L / 181,500 g/mol 
    = 1.45 x 10-7 mols/L = 145 nM 
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41R5’ construct –  
10 ng/uL = 1 x 10-8 g/uL 
1 x 10-8 g / 1 x 10-6 L = 0.01 g/L 
Molarity = 0.01 g/L / 181,500 g/mol  
    = 5.51 x 10-8 mol/L 
    = 55.1 nM  
41F3’ : 41R5’  
1        :        3 = 4  
10 ng (total amount of DNA per reaction) / 4 = 2.5 
1 x 2.5 = 2.5 ng 
3 x 2.5 = 7.5 ng  














The goal of this study was to delineate the molecular mechanisms by which IGF1-AKT-
activated CAK complex promotes cardiomyocyte proliferation. Last semester, I observed 
that cardiomyocyte proliferation is mediated by IGF1-AKT-CAK. Therefore, my aim this 
semester was to further characterize the mechanisms by which IGF1-mediated 
cardiomyocyte proliferation occurs. To achieve this, the CDKs and cyclins activated by 
IGF-1 were identified and the effect of CAK knockdown and AKT inhibition on CDK 
phosphorylation and cyclin expression was evaluated.    
IGF-1 promotes cardiomyocyte proliferation via the CAK complex 
I began by validating my finding from last semester in which it was observed that IGF-1 
promotes cardiomyocyte proliferation via the CAK complex. Upon knocking down 
CDK7 and CCNH, knockdown was confirmed via Western blot analysis. 
 
Figure 1. Western blot analysis for CDK7 and cyclin H upon knockdown; B-tubulin was used as the 
loading control. n = 2 
Following confirmation of knockdown, a proliferation assay was performed to validate 
the role of the CAK complex in IGF-1-mediated cardiomyocyte proliferation, as 
demonstrated last semester (Figure 2., compare bars “IGF-1 (CAK Knockdown)” [mean 
= 47.68%] and “IGF-1+siNeg+Lipofectamine” [mean = 62.73%] along with the 
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remainder of the controls [H2O/no treatment, mean = 59.3%; lipofectamine, mean = 
57.86%; siRNA negative control #1, mean = 58.22%; siRNA negative control #2, mean = 
53.57%; HASF (CAK knockdown), mean = 63.72%; HASF+siNeg+Lipofectamine, mean 
= 68.49%; LL-37 (CAK knockdown), mean = 61.09%; LL-37+siNeg+Lipofectamine, 
mean = 67.36%]) and Figure 3., compare images 7 and 8, along with the remainder of 
the controls [images 1 – 6; 9 - 10]). Significance was found between CAK knockdown 
H9C2s treated with IGF-1 and H9C2s containing a functional CAK complex treated with 
IGF-1, siRNA negative control, and Lipofectamine (p-value: 0.0285).             
Figure 2. BrdU incorporation rates of CAK knockdown H9C2s induced with HASF, IGF-1, and LL-37;  








Figure 3. Immunohistochemical analysis of CAK knockdown H9C2s induced with HASF, IGF-1, and LL-
37. BrdU staining was utilized to assess rates of incorporation in cells containing and lacking functional 
CAK complexes. Left to right, top to bottom:1) no treatment; 2) Lipofectamine; 3) siNeg #1; 4) siNeg #2; 
5) HASF (CAK knockdown); 6) HASF+siNeg+Lipofectamine; 7) IGF-1 (CAK knockdown); 8) IGF-
1+siNeg+Lipofectamine; 9) LL-37 (CAK knockdown); 10) LL-37+siNeg+Lipofectamine; n = 3 
 
IGF-1 reduces H9C2 proliferation via the AKT signaling pathway 
Next, I validated the finding from last semester in which it was observed that AKT 
inhibition reduces H9C2 proliferation. Cells were incubated with the pERK inhibitor, 
U0126, and the AKT inhibitor, triciribine. HASF, IGF-1, and LL37 were used to enhance 
cardiomyocyte proliferation. As demonstrated in Figure 4., treatment with ligands caused 
cells to exhibit average BrdU incorporation rates of 87.14%, 81.80%, and 87.1% for 
HASF, IGF-1, and LL-37, respectively, compared to the control, 78.87%. However, 
when treated with triciribine (Figure 5.), the average BrdU incorporation rates for H9C2s 
induced with HASF, IGF-1, and LL-37 are 65.15%, 71.74%, and 85.02%, respectively. 
When treated with U0126, the average BrdU incorporation rates of H9C2s induced with 
HASF, IGF-1, and LL-37 are 72.61%, 81.53%, and 81.55%, respectively. Significance 
was found between H9C2s treated with IGF-1 and H9C2s treated with IGF-1+triciribine 
(p-value: 0.03705).    
 20 
Figure 4. BrdU incorporation rates of H9C2s induced with HASF, IGF-1, and LL-37; n = 3. 
 
 




IGF-1 enhances phosphorylation of CDK2, but does not enhance cyclin E1 expression 
Western blot analysis was utilized to evaluate the cyclins activated by IGF-1. Blots were 
probed with cyclin A2, cyclin B1, and cyclin E1 antibodies, however, only the cyclin E1 
bands were noticeably visible. As demonstrated in Figure 6, (compare left band and bar, 
respectively, “H2O (Cont.)” with right band and bar, respectively, “IGF-1”), IGF-1 did 
not enhance cyclin E1 expression.   
 
	
Figure 6. Western blot analysis and protein quantitation for H9C2s treated with IGF-1 and probed 
with anti-cyclin E1; B-tubulin was used as the loading control; n = 3.  
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Blots were then probed with pCDK2. As demonstrated in Figure 7, (compare left band 
and bar, respectively, “H2O (Cont.)” with right band and bar, respectively, “IGF-1”), 
IGF-1 enhanced phosphorylation of CDK2 by ~30%.   
  
 
Figure 7. Western blot analysis and protein quantitation for H9C2s treated with IGF-1 
and probed with anti-pCDK2; B-tubulin was used as the loading control; n = 3. 
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CAK Knockdown Resulted in Uninterpretable Data  
 
The effect of CAK knockdown on cyclin E1 expression and phosphorylation of CDK2 
was evaluated via Western blot analysis. Unfortunately, both the siRNA negative control 
and the transfection reagent lipofectamine impacted cyclin E1 expression and CDK2 
phosphorylation (Figure 8, compare left band and bar “no treatment,” center band and 
bar “si(-),” and right band and bar “lipofectamine”). Thus, it was difficult to determine if 
IGF-1 modified cyclin E1 expression and CDK2 phosphorylation in the absence of the 
CAK complex in H9C2s induced with IGF-1 (not shown).  
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Figure 8. Western blot analysis and protein quantitation for H9C2s treated with transfection reagents and 
probed with anti-cyclin E1 and –pCDK2. CAK knockdown H9C2s induced with IGF-1 not shown due to 
lack of interpretability; n = 2.  
 
 
AKT inhibits phosphorylation of IGF-1-activated CDK2, but does not inhibit cyclin E1 
expression. 
Western blot analysis was utilized to assess the effect of AKT inhibition on cyclin E1 
expression and CDK2 phosphorylation. Cells were incubated with the AKT inhibitor, 
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triciribine (Tri). This AKT pharmacological inhibitor had no effect on cyclin E1 
expression following IGF-1 treatment (Figure 9., compare left band and bar, “H2O 
(Cont.)” center band and bar, “(IGF-1)” and right band and bar, “IGF-1+Tri.,”).  
 
	
Figure 9. Western blot analysis and protein quantitation for IGF-1-induced H9C2s treated with 
triciribine and probed with anti-cyclin E1; B-tubulin was used as the loading control; n = 3. 
 
In contrast, triciribine markedly inhibited IGF-1 mediated phosphorylation of CDK2 
(Figure 10., compare left band and bar, “H2O (Cont.)” center band and bar, “(IGF-1)” 





Figure 10. Western blot analysis and protein quantitation for IGF-1-induced H9C2s treated with triciribine 






Designing mutant CDK7 variants to validate the role of CAK in IGF-1 mediated 
proliferation. 
To validate CAK-mediated phosphorylation of CDKs and activation of cyclins, 
transfection of groups of cardiomyocytes with a dominant negative form of CAK and a 
constitutively active form of CAK would have been performed. IGF-1 would have been 
added to the wells of a 12-well plate to stimulate proliferation. Following transfection, 
Western blot analysis would have been performed to detect CDKs and cyclins. 
Afterwards, BrdU proliferation assays would have been performed as a final readout. 
 
In order to create dominant negative and constitutively active CDK7 constructs for 
transfection into H9C2s, site-directed mutagenesis via DpnI cloning was first employed. 
Despite several attempts where annealing temperature, denaturation, and elongation 
times were altered, as well as cycle number, no bacterial colonies were observed. This 
was not due to bacterial transformation as the positive control DNA yielded colonies.  
 
As DpnI cloning was not working as intended, an alternative two-step strategy was 
utilized. In the first step, PCR was performed using sequencing primers VP 1.5 (5’) and 
XL39 (3’) and mutant primers to produce four individual constructs – 41F3’, 41R5’, 
137F3’, 137R5’ (Figure 11). In the second step, respective constructs were combined 
(i.e. 41F3’+41R5’ and 137F3’+137R5’), and after three rounds without primers to allow 
the polymerase to fill-in the overhangs, the DNA was amplified with the sequencing 
primers, and subsequently run on an agarose gel. As depicted in Figure 12, the control 
lane (41F3’) contains a band at 1500 bp, indicative of parental plasmid contamination.  
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Figure 11. Gel electrophoresis for individual constructs 41R5’,  
41F3’, 137R5’, and 137F3’ amplified via PCR.   
                           
Figure 12. Gel electrophoresis for combined constructs 41F3’+41R5’ and 
137F3’+137R5’ in addition to control 41F3’. Presence of band in control lane is 




To prevent parental plasmid contamination, 41F3’, 41R5’, 137F3’, and 137R5’ bands 
were gel purified, and purified DNA was amplified as described above. PCR products 
were then visualized (Figure. 13). 
 
Figure 13. Gel electrophoresis for combined constructs 41R5’+41F3’ and 137R5’+137F3’ in addition to 
controls H2O, 41R5’, 41F3’, 137R5’, and 137F3’. Presence of bands in 41R5’, 137R5’, and 137F3’ lanes 
indicates plasmid contamination.  
 
Plasmid contamination persisted (bands present in 41R5’, 137R5’, and 137F3’ lanes), 
and therefore further optimization was necessary. Three alternatives were attempted: 
1) PCR cycle number reduced from 35 to 25  
2) PCR performed with respective constructs at approximately equal molarities 
and no more than 10 ng DNA per lane (Figure 14), and finally,  
3) PCR performed with double Mg++ concentration (Figure 15).  
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Plasmid contamination was the least in PCR #3 (Figure 15), as demonstrated by the lack 
of bands in the 41R5’ and 41F3’ lanes and the presence of faint bands in the 137R5’ and 




Figure 14. Gel electrophoresis for combined constructs 41R5’+41F3’ and 137R5’+137F3’ in 
addition to controls H2O, 41R5’, 41F3’, 137R5’, and 137F3’. Respective constructs at 
approximately equal molarities and no more than 10 ng DNA per lane in addition to PCR cycle 




Figure 15. Gel electrophoresis for combined constructs 41R5’+41F3’ and 137R5’+137F3’ in addition    
to controls H2O, 41R5’, 41F3’, 137R5’, and 137F3’. Mg++ concentration doubled (from 1.5 mM to 3 
mM). Respective constructs at approximately equal molarities and no more than 10 ng DNA per 































The role of CAK and AKT in stimulated cardiomyocyte proliferation. 
The Dzau lab has previously demonstrated that the novel paracrine protein HASF 
promotes neonatal and adult cardiomyocyte proliferation. During semester one, I initially 
hypothesized that HASF mediated cardiomyocyte proliferation via the CAK complex. 
CAK knockdown data, however, did not support that hypothesis – when performing 
BrdU staining for cell proliferation, I expected to see decreased proliferation in CAK 
knockdown cells induced with HASF. Instead, I observed decreased proliferation only in 
cells induced with IGF-1. This, along with the significance found between CAK 
knockdown H9C2s treated with IGF-1 and H9C2s containing a functional CAK complex 
treated with IGF-1, siRNA negative control, and Lipofectamine (p-value: 0.0285), 
indicated that IGF-1 promotes cardiomyocyte proliferation via the CAK complex and 
HASF does not, suggesting that the CAK complex is AKT-dependent.  
 
The data represented in Figure 5 validated the importance of AKT in IGF1-mediated 
cardiomyocyte proliferation, as the AKT inhibitor triciribine reduced the proliferative 
effect of IGF-1 (significance between H9C2s treated with IGF-1 and H9C2s treated with 
IGF-1+triciribine – p-value: 0.03705), but the pERK inhibitor, U0126, did not.  
 
The role of IGF-1, AKT, and CAK in the cardiomyocyte cell cycle. 
To identify the CDKs and cyclins activated by IGF-1 in cardiomyocytes, I initially 
probed Western blots with antibodies against the most essential cyclins in the mammalian 
cell cycle, cyclins A2, B1, and E1. The poor quality of anti-cyclins A2 and B1 
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confounded interpretation, and therefore, the remainder of my experiments were solely 
focused on cyclin E1 and its corresponding CDK, CDK2.  
 
The data represented in Figures 6 – 7 strongly suggests that the proliferative effect of 
IGF-1 is not associated with cyclin E1 expression, but rather with the phosphorylation of 
CDK2, as cyclin E1 expression did not increase in cardiomyocytes induced with IGF-1 
but phosphorylation of CDK2 increased. This finding agrees with cell cycle literature – 
when mammalian cells enter the cell cycle, endogenous expression of cyclins is not 
enhanced (Lodish, 2014; p. 884). Instead, CDKs associate with their respective cyclins 
and undergo phosphorylation, resulting in activation of their kinase activity (Lodish, 
2014; p. 885).   
 
As Figure 10 illustrates, CDK2 phosphorylation appears to be AKT-dependent, as 
treatment with triciribine decreased pCDK2 to basal levels of phosphorylation. 
Furthermore, the phospho-CDK2 antibody used in this study detected phosphorylation by 
CAK. Considering that this phosphorylation site (Thr 160) was modified by AKT 
inhibition suggests that CDK2 activity is controlled by AKT via the CAK complex.  
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To confirm the role of the CAK complex in AKT-dependent CDK2 phosphorylation,  the 
CAK complex in cardiomyocytes was knocked down and probed with anti-pCDK2 and 
anti-cyclin E1. Protein quantitation data showed that both siRNA negative control and 
lipofectamine strongly affected CDK2 phosphorylation and cyclin E1 expression. 
Considering these effects from the controls it would be difficult to assess the effect of 
CAK knockdown on CDK2 phosphorylation and cyclin E1 expression in cardiomyocytes 
induced with IGF-1. Moreover, >90% ablation of CAK may be necessary for my 
experiments (Sale, 2006), and to achieve this, optimization of the transfection conditions 
or using CRISPR to gene-edit the cardiomyocytes would be necessary.  
 
Additional validation of IGF1-AKT-CAK-mediated CDK2 phosphorylation will require 
inhibiting CDK2 phosphorylation. This could be achieved by utilizing the CDK2 
inhibitor Flavopiridol (Selleckchem) and performing Western blot analysis. To confirm 
the role of IGF1-AKT-CAK-activated CDK2 in cardiomyocyte proliferation, BrdU 
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proliferation assays would be performed on Flavopiridol-treated cardiomyocytes; 
minimal proliferative activity will be indicative of a role for CDK2.     
 
The use of sequencing primers, an alternate to traditional site-directed mutagenesis. 
When attempting to introduce dominant negative and constitiutievly active mutations into 
a CDK7 plasmid, DpnI site-directed mutagenesis was unsuccesful. This was despite 
altering thermocycling conditions in a number of ways, including increasing the 
annealing temperature to reduce non-specfic binding; increasing denaturation time to 
allow for a more complete denaturing of DNA and sufficient access for primers to anneal; 
increasing elongation time as well as increasing cycle number (Roche, 2016). To verify 
efficient bacterial transformation, parental plasmid DNA was diluted 1:100, transformed, 
and plated on an agar plate. Bacterial colonies were present the next day, suggesting that 
the strategy to adjust PCR conditions was the correct option. However, none of these 
modifications worked so an alternative two-step strategy was adopted. This involved the 
use of sequencing primers to sequencing sites within the plasmid, which are well-
established with respect to PCR amplification. They are also useful for restriction digests 
as they lie far outside the cloning sites. Restriction enzymes require a certain number of 
base pairs on the 5’end to cut successfully (New England Biosciences, 2016). Employing 
sequencing primers guarentees the presence of significant stretches of DNA on either side 
of multiple cloning sites and thereby, successful restriction enzyme digests.   
 
There was an issue with parental plasmid contamination, necessitating another series of 
PCR optimization steps – reducing cycle number from 35 to 25 to reduce amplification of 
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contaminants; gel purification of individual construct bands to ensure isolation of the 
specific DNA fragments in the absence of the contaminating parental plasmid which 
would run at a higher molecular weight; using equal molarities of the respective 
constructs for amplification as well as modifying DNA concentration to reduce non-
specific amplification. These approaches were unsuccessful in preventing amplification 
from contaminating parental plasmid. Interestingly doubling the concentration of Mg++, 
in addition to the previous alterations described above, showed only a limited amount of 
amplification from the parental plasmid. This may be due to enhancement activity of the 
polymerase (Caister Academic Press, 2016). Increasing Mg++ reduces the ability of 
DNA to denature, thus the higher Mg++ concentration may have prevented denaturation 
of the larger sized plasmid whilst still allowing primer access to the much smaller DNA 
fragments. 
 
The next step would be to digest the amplicon and ligate it into the empty parental 
plasmid, perform bacterial transformation, and further characterize kanamycin resistant 
colonies for the presence of the insert and faithful copying of the DNA (i.e. sequencing to 
ensure the correct sequence). Once the plasmid DNA is isolated cardiomyocytes would 
be transfected with plasmids that contain the dominant negative form of CAK or the 
constitutively active form of CAK. Transfection with the empty plasmid and a plasmid 
containing wild-type CDK7 would serve as controls. Following transfection, Western 
blot analysis would be performed as described above on all groups to ensure that 
mutations were affecting activity of CDK7 and examine how this modifies CDK 
phosphorylation and cyclin expression. Afterwards, BrdU proliferation assays would be 
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performed as a final readout. I expect to see the highest amount of proliferation in wells 
with cells containing the constitutively active CAK construct and the lowest amount of 
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Journal of of Physiology – Lung Cellular and Molecular Physiology. 2015 Dec 15; 309(12):1467-77. 
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American Journal of Respiratory Medicine. 2014 Jun; 50(6):1010-20 
 
4) Baksh S, Loesser K. “Cell Fusion and Growth Factor IGF in Myocardial Repair.”  
Abstract and oral presentation delivered at the Virginia Academy of Science,  







1) Moon K, Baksh S, Punjabi N, Shimoda LA. “Calcium Signaling and Glucose Output In Hepatocytes 





1) Baksh S, Hodgkinson C, Bareja A, Yusif J, Patel S, Dzau VJ. “Effects of Biased Ligand Signaling on 
Cardiomyocyte Proliferation.” Johns Hopkins Biotechnology Research Symposium 2016.  
 
2) Maman S, Baksh S, Yun X, Jiang H, Shimoda LA. “Mechanisms Involved in Hypoxia-Inducible Factor 
1 Dependent Upregulation of Aquaporin 1.” Hopkins C.A.R.E.S Summer Symposium 2014. 
 
3) Maman S, Baksh S, Yun X, Jiang H, Shimoda LA. “The Role of Hypoxia-Inducible Factor 1 in 
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ADDITIONAL SKILLS  
 
Computer Skills – Microsoft Word 2016, Excel 2016, and PowerPoint 2016  
 
Languages – Fluent in Bengali  
	
